Novartis Rhapsido CIndU Data: Remibrutinib Shows Sustained Efficacy Through Week 52 in Phase III RemIND Study
Novartis reported 52-week Phase III RemIND results for Rhapsido (remibrutinib) in chronic inducible urticaria. Response rates held through Week 52 across symptomatic dermographism, cold urticaria and cholinergic urticaria, and additional regulatory submissions are planned.
